Medical/Pharmaceuticals
WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong
* Hong Kong Science and Technology Parks Corporation (HKSTPC) and WuXi XDC signed a cooperation framework agreement to jointly promote the establishment of a contract research, development and manufacturing organization(CRDMO) value chain inHong Kong. * HKSTP Park companies will leverage WuXi...
2023-10-18 11:00
2373
First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
SUZHOU, China and ROCKVILLE, Md., Oct. 17, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the registrational Phase III study (HQP1351AG...
2023-10-18 10:11
2193
Ubie's new Generative AI feature for doctors effortlessly summarizes patient findings and streamlines medical record documentation with a 90% User Satisfaction rate.
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Ubie
2023-10-17 23:00
3422
Congratulations to Sanyou Bio for achieving ISO9001 & IPMS certifications
SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd is pleased to announce inOctober 2023, we have obtained ISO 9001 and IPMS certifications. These certifications emphasize Sanyou's commitment to consistency, reliability, and accountability in our innovative biopharmaceuti...
2023-10-17 21:00
2103
Global Healthcare Startup Sky Labs Attracts Investments Totaling KRW 20.7 Billion in a Series C Round
- Major investors include Korea Development Bank (KDB), K2 Investment Partners, DEVSISTERS VENTURES, SJG Partners, and OPENWATER INVESTMENT - Distribution of 'CART BP,' a ring-type cuffless blood pressure monitor that enables continuous blood pressure measurement and monitoring 24/7, will be ful...
2023-10-17 20:00
2612
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration
BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announ...
2023-10-17 08:00
16218
Abbisko will debut two blockbuster clinical research results at the 2023 European Society for Medical Oncology（ESMO）
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib（ABSK011）and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with...
2023-10-16 21:50
2734
New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023
- Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeut...
2023-10-16 21:10
2802
TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment
Company champions long-acting HIV therapy with new biologic drug TMB-365/380
combination; after favorable results of Phase1b/2a, company plans to accelerate
Phase 2 clincial study to expedite path to market
TAIPEI, Oct. 16, 2023 /PRNewswire/ -- TaiMed Biologics
2023-10-16 21:00
2613
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapie...
2023-10-16 20:00
2669
SeekIn Presents New Validation Studies of OncoSeek Multi-cancer Early Detection test at Early Detection of Cancer Conference in London
Two Sample Types, Three Different Platforms, Five Independent Cohorts of ~10,000 Cancer Patients and Non-cancer Individuals with Diverse Ethnic Backgrounds Validate OncoSeek's Ability to Detect Multiple Cancer Types and Predict Tissue of Origin of Cancers SHENZHEN, China, Oct. 16, 2023 /PRNewswi...
2023-10-16 20:00
2515
Abbisko presented two preclinical research results at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR)
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko" hereafter) announced that the results of the company's two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC) be held inBoston, U.S.. These two research...
2023-10-16 18:20
2376
CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China
BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK),a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare disease and rare oncology, ...
2023-10-16 13:38
2375
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL
SUZHOU, China, and ROCKVILLE, Md., Oct. 15, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has entered into a clinical collaboration ...
2023-10-16 09:23
2774
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement
CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company with a breakthrough technology to restore defective blood vessels, announced ...
2023-10-13 23:26
3543
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Acti...
2023-10-13 20:00
3439
Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata
* IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile * IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD) * An interim data readout in AA is expected in Q3 20...
2023-10-13 20:00
3026
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New data presented on novel orally bioavailable p300-selective degraders showing significant anti-tumor activity in preclinical models of androgen receptor (AR) positive prostate cancer SEOUL, South Korea and KING OF PRUSSIA, Pa., Oct. 12, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global bio...
2023-10-13 09:00
3151
Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE
ROCKVILLE, Md. and SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China ...
2023-10-13 08:22
2593
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy
.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 .. Phase 3 results expected in 2025 .. Exclusive license for AU, NZ, Singapore, Mal...
2023-10-13 03:00
4433
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
62639
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
58637
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
55754
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
25227
